Intact Investment Management Inc. Invests $420,000 in Moderna, Inc. (NASDAQ:MRNA)

Intact Investment Management Inc. acquired a new stake in Moderna, Inc. (NASDAQ:MRNA - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 10,100 shares of the company's stock, valued at approximately $420,000.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. State Street Corp raised its holdings in shares of Moderna by 12.1% in the third quarter. State Street Corp now owns 16,847,212 shares of the company's stock valued at $1,125,899,000 after acquiring an additional 1,823,276 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Moderna by 2.6% in the third quarter. Geode Capital Management LLC now owns 7,069,580 shares of the company's stock valued at $470,670,000 after acquiring an additional 178,115 shares in the last quarter. Wellington Management Group LLP raised its holdings in shares of Moderna by 21.0% in the third quarter. Wellington Management Group LLP now owns 5,224,685 shares of the company's stock valued at $349,166,000 after acquiring an additional 906,114 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Moderna by 0.5% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,890,812 shares of the company's stock valued at $260,023,000 after acquiring an additional 19,819 shares in the last quarter. Finally, The Manufacturers Life Insurance Company grew its stake in Moderna by 6.2% in the third quarter. The Manufacturers Life Insurance Company now owns 3,073,934 shares of the company's stock valued at $205,431,000 after purchasing an additional 178,939 shares during the last quarter. 75.33% of the stock is currently owned by institutional investors.

Remove Ads

Wall Street Analysts Forecast Growth

Several research firms have issued reports on MRNA. Berenberg Bank lifted their target price on Moderna from $33.00 to $42.00 and gave the company a "hold" rating in a research note on Thursday, January 16th. Bank of America cut their target price on Moderna from $41.00 to $34.00 and set an "underperform" rating on the stock in a research note on Tuesday, February 11th. Royal Bank of Canada reiterated a "sector perform" rating and issued a $40.00 target price on shares of Moderna in a research note on Tuesday, February 18th. Leerink Partners cut their target price on Moderna from $31.00 to $27.00 and set an "underweight" rating on the stock in a research note on Thursday, January 16th. Finally, Citigroup assumed coverage on Moderna in a research note on Thursday, March 13th. They issued a "neutral" rating and a $40.00 target price on the stock. Four analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, three have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $59.60.

Moderna Price Performance

NASDAQ:MRNA traded down $0.87 during trading hours on Thursday, reaching $32.45. The company had a trading volume of 5,612,930 shares, compared to its average volume of 6,572,057. Moderna, Inc. has a 1-year low of $29.25 and a 1-year high of $170.47. The firm has a market cap of $12.52 billion, a PE ratio of -3.50 and a beta of 1.86. The business's 50 day moving average price is $35.31 and its 200-day moving average price is $46.45.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.